Bicara Therapeutics Reports Strong IPO and Clinical Advancements

TipRanksNov 14 12:43

Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $47

Futu NewsNov 13 21:36 · Ratings

Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $36

Futu NewsNov 13 21:36 · Ratings

Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Raises Target Price to $36

Futu NewsNov 13 20:35 · Ratings

Express News | Bicara Therapeutics Inc : Morgan Stanley Raises Target Price to $36 From $35

BreakingsNov 13 18:31

Bicara Therapeutics | 10-Q: Quarterly report

SECNov 13 05:09 · Announcements